RE:RE:RE:RE:RE:RE:RE:RE:RE:Re: Up 39.39% in one weekMany pharmaceuticals are derived from natural sources. CZO characterizes and standardizes the active ingredient like avenanthramide and makes phamaceutical-grade product. It takes a pharmaceutical approach.
The avenanthramide currently in trials has nothing to do with PGX to our knowledge. They have said that they have explored newer generation PGX carriers with avenanthramide with promising results but that is likey to be explored later in clinical trials once avenanthramide by itself is understood.
PGX-YBG and PGX-Alginate can also be used to deliver pharmaceuticals. For fibrosis PGX-YBG has been studied as a carrier with nintedanib which is one of the two major drugs currently marketed for fibrosis. For COVID an anti-inflammatory drug currently used has been investigated with PGX.
"To advance this promising technology into clinical trials, the aim of the project is to optimize the delivery of PGX-YBG to the lung and validate its performance for reducing lung fibrosis, both alone and loaded with an anti-inflammatory drug currently used for COVID-19 therapy." news release
Tencents wrote: That's correct
the 2 ingredients are natural products with neutritional and pharmaceutical activities
the ceo words are - natural ingredients for neutrition/ pharmaceutical use
that's the word of the ceo. - it's fair to assume he knows what business he is running
in fact it's the huge differential factor of czo -
the trials are to support the claims of the 2 natural ingredients as modified by pgx technology- nothing to do with biopharma
the expertise mentioned are those of the phd s on the board and other scientists in the organisation
That expertise plays some roles in manageing the portfolio
but it's not the product